- Home
- ANTX vs FEMY Comparison
ANTX vs FEMY Comparison
Compare ANTX & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- FEMY
- Stock Information
- Founded
- ANTX 2017
- FEMY 2004
- Country
- ANTX United States
- FEMY United States
- Employees
- ANTX N/A
- FEMY N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- FEMY Medical/Dental Instruments
- Sector
- ANTX Health Care
- FEMY Health Care
- Exchange
- ANTX Nasdaq
- FEMY Nasdaq
- Market Cap
- ANTX 33.2M
- FEMY 31.9M
- IPO Year
- ANTX 2022
- FEMY 2021
- Fundamental
- Price
- ANTX $1.07
- FEMY $0.96
- Analyst Decision
- ANTX Buy
- FEMY Strong Buy
- Analyst Count
- ANTX 2
- FEMY 3
- Target Price
- ANTX $2.00
- FEMY $8.67
- AVG Volume (30 Days)
- ANTX 283.5K
- FEMY 369.9K
- Earning Date
- ANTX 08-12-2025
- FEMY 08-07-2025
- Dividend Yield
- ANTX N/A
- FEMY N/A
- EPS Growth
- ANTX N/A
- FEMY N/A
- EPS
- ANTX N/A
- FEMY N/A
- Revenue
- ANTX N/A
- FEMY $1,699,232.00
- Revenue This Year
- ANTX N/A
- FEMY $231.84
- Revenue Next Year
- ANTX N/A
- FEMY $245.28
- P/E Ratio
- ANTX N/A
- FEMY N/A
- Revenue Growth
- ANTX N/A
- FEMY 61.97
- 52 Week Low
- ANTX $0.87
- FEMY $0.69
- 52 Week High
- ANTX $3.07
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- ANTX 42.04
- FEMY 48.09
- Support Level
- ANTX $1.07
- FEMY $0.91
- Resistance Level
- ANTX $1.11
- FEMY $0.95
- Average True Range (ATR)
- ANTX 0.04
- FEMY 0.06
- MACD
- ANTX 0.00
- FEMY 0.01
- Stochastic Oscillator
- ANTX 0.00
- FEMY 31.16
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.